NCT01343043 - A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 27, 2012

Primary Completion Date

June 18, 2019

Study Completion Date

June 18, 2019

Conditions

Neoplasms

Interventions

DRUG

NY-ESO-1(c259)T Cells

Lymphodepleting chemotherapy followed by infusion with NY-ESO-1(c259) transduced autologous T cells. Subjects will receive one infusion of NY-ESO-1 genetically engineered T cells on Day 0.

DRUG

Fludarabine

Fludarabine will be used as lymphodepleting chemotherapy.

DRUG

Cyclophosphamide

Cyclophosphamide will be used as lymphodepleting chemotherapy.

Trial Locations (8)

10065

GSK Investigational Site, New York

20892

GSK Investigational Site, Bethesda

33136

GSK Investigational Site, Miami

33612

GSK Investigational Site, Tampa

63110

GSK Investigational Site, St Louis

77030

GSK Investigational Site, Houston

91010

GSK Investigational Site, Duarte

02114

GSK Investigational Site, Boston